Practical Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement
Webinar | English
Image For Activity Cover
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered
This webinar will give a summary of recently published ESTRO & ASTRO practice guidelines about radiotherapy for lung cancer in the COVID-19 pandemic, whether radiotherapy can or should be adapted, and if so how should this be done. We will address questions about whether radiotherapy can be delayed, fractionation of radiotherapy, multimodality treatment strategies and handling of COVID-19 positive patients. Considering a pandemic scenario characterized by a shortage of radiotherapy resources, we will discuss factors influencing patient prioritization and triage. These questions will be addressed in the format of six clinical cases with curative or palliative treatment for NSCLC and SCLC. 
The target audience for this program includes radiation oncologists and clinical oncologists practicing lung cancer radiotherapy, as well as all disciplines with an interest in lung cancer radiotherapy.
Upon completion of this activity, the participants should be able to: 
  • Reviewed the recently published ESTRO & ASTRO practice guidelines about radiotherapy for lung cancer in the COVID-19 pandemic. 
  • Discuss whether radiotherapy can or should be adapted, and if so how should this be done. We will address questions about whether radiotherapy can be delayed, fractionation of radiotherapy, multimodality treatment strategies and handling of COVID-19 positive patients.
  • Prof Corinne Faivre-Finn FRCR, MD, PhD, Professor of Thoracic Radiation Oncology, Honorary Consultant Clinical Oncologist, The Christie NHS Foundation Trust
  • Matthias Guckenberger, MD, Department of Radiation Oncology, University Hospital Zurich (UHZ), University of Zurich
  • David Palma, MD, MSc, PhD, FRPC, Division of Radiation Oncology, Western University, London, Canada

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.
Powered By